Biosynthesis: The Science That May Unlock the Medical Potential of Cannabis

Original article seen here: http://www.visualcapitalist.com/biosynthesis-medical-potential-cannabis/ Attitudes are changing fast on cannabis, and investors are taking note. With the birth of legal recreational markets in places like California and a growing appreciation for the medical … [Read more...]

InMed $IN Names Mauro Maccarrone to Advisory Board

(CSE: IN; OTCQB: IMLFF) InMed Pharmaceuticals Inc., a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, is pleased to announce the addition of Dr. Mauro Maccarrone to its Scientific Advisory Board. Dr. Mauro Maccarrone is Professor … [Read more...]

InMed $IN Files Patent for Pain Treatment Program

(CSE: IN; OTCQB: IMLFF) InMed Pharmaceuticals, Inc, a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced the filing of a provisional patent application in the United States for INM-405 and other unique compositions as … [Read more...]

InMed $IN on the Front Lines of Cannabinoid Biosynthesis

(CSE: IN, OTCQB: IMLFF) InMed Pharmaceuticals Inc.  has released today an update on its proprietary research into synthesizing cannabinoids for use as pharmaceuticals. The Company has successfully demonstrated the capacity to reproduce any and all of the more than  90 cannabinoids through its … [Read more...]

InMed $IN Added to CSE25 Index

(CSE: IN; OTCQB: IMLFF) InMed Pharmaceuticals, Inc. is pleased to announce that InMed has been included in the CSE25 Index. InMed qualified for the index as one of the twenty-five largest companies in the CSE Composite Index. About the CSE25 Index  On September 18, 2017, the Canadian … [Read more...]